CSS
KNSA icon

Cubist Systematic Strategies’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Cubist Systematic Strategies’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$14.8M Sell
381,319
-276,156
-42% -$8.97M 0.07% 388
2025
Q2 		$18.2M Buy
657,475
+447,536
+213% +$11.4M 0.08% 331
2025
Q1 		$4.66M Buy
+209,939
New +$4.32M 0.03% 923
2024
Q2 		– Sell
-102,997
Closed -$2.03M – 3516
2024
Q1 		$2.03M Buy
102,997
+67,081
+187% +$1.31M 0.01% 1635
2023
Q4 		$630K Buy
+35,916
New +$590K ﹤0.01% 2393
2023
Q3 		– Sell
-40,294
Closed -$567K – 3655
2023
Q2 		$567K Buy
+40,294
New +$539K ﹤0.01% 2313
2023
Q1 		– Sell
-110,620
Closed -$1.66M – 4175
2022
Q4 		$1.66M Buy
110,620
+58,469
+112% +$851K 0.01% 2015
2022
Q3 		$670K Buy
52,151
+18,236
+54% +$208K ﹤0.01% 2939
2022
Q2 		$329K Sell
33,915
-8,416
-20% -$78.5K ﹤0.01% 3371
2022
Q1 		$421K Sell
42,331
-11,629
-22% -$123K ﹤0.01% 2644
2021
Q4 		$635K Buy
53,960
+13,554
+34% +$167K 0.01% 2270
2021
Q3 		$460K Buy
40,406
+24,313
+151% +$317K 0.01% 2088
2021
Q2 		$224K Sell
16,093
-5,936
-27% -$90.2K ﹤0.01% 2495
2021
Q1 		$408K Sell
22,029
-7,724
-26% -$158K 0.01% 2074
2020
Q4 		$526K Buy
29,753
+5,873
+25% +$103K 0.01% 1747
2020
Q3 		$366K Sell
23,880
-636
-3% -$11.9K 0.01% 1910
2020
Q2 		$625K Buy
24,516
+9,636
+65% +$201K 0.01% 1470
2020
Q1 		$230K Sell
14,880
-825
-5% -$12.9K 0.01% 1653
2019
Q4 		$174K Buy
15,705
+15,363
+4,492% +$133K ﹤0.01% 2070
2019
Q3 		$3K Sell
342
-358
-51% -$3.96K ﹤0.01% 2171
2019
Q2 		$9K Buy
+700
New +$10.9K ﹤0.01% 2407
2018
Q3 		– Sell
-6,619
Closed -$115K – 1995
2018
Q2 		$115K Buy
+6,619
New +$120K 0.01% 1499

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cubist Systematic Strategies's KNSA Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Kiniksa Pharmaceuticals (KNSA) stake by 42% in Q3 2025, selling an estimated $8.97M and leaving 381,319 shares worth $14.8M. The position accounts for 0.07% of the portfolio, ranked #388.

Cubist Systematic Strategies first reported a position in KNSA in Q2 2018 and has held it in 22 quarters since. The position peaked at $18.2M in Q2 2025. 204 funds tracked by Wall St. Rank hold KNSA as of Q3 2025.

  • Cubist Systematic Strategies held 381,319 shares of Kiniksa Pharmaceuticals worth $14.8M as of Q3 2025.
  • Cubist Systematic Strategies sold 276,156 Kiniksa Pharmaceuticals shares in Q3 2025, an estimated $8.97M.
  • Kiniksa Pharmaceuticals made up 0.07% of Cubist Systematic Strategies's portfolio in Q3 2025, its #388 holding.
  • Cubist Systematic Strategies first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 22 quarters since.
  • Cubist Systematic Strategies's Kiniksa Pharmaceuticals position peaked at $18.2M in Q2 2025.
  • 204 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.